menu
    • menu
    [{"orgOrder":0,"company":"Church & Dwight Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Dentifrice","moa":"Bacterial biofilm","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Church & Dwight Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Church & Dwight Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Church & Dwight Co \/ Undisclosed"},{"orgOrder":0,"company":"PROCTER AND GAMBLE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sodium Fluoride","moa":"Hydroxyapatite","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"PROCTER AND GAMBLE","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROCTER AND GAMBLE \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PROCTER AND GAMBLE \/ Undisclosed"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Silver Diamine Fluoride","moa":"Immune","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of Washington"},{"orgOrder":0,"company":"Indiana University","sponsor":"Water Pik, Inc. | Delta Dental Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Powder","sponsorNew":"Indiana University \/ Water Pik, Inc. | Delta Dental Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University \/ Water Pik, Inc. | Delta Dental Foundation"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AAV2-hAQP1","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Undisclosed"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AAV2-hAQP1","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Undisclosed"},{"orgOrder":0,"company":"AngioLab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ALH-L1005","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"AngioLab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AngioLab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AngioLab \/ Undisclosed"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Colgate Maximum Cavity Protection Plus Sugar Acid Neutralizer","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"HysensBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ Undisclosed"},{"orgOrder":0,"company":"HysensBio","sponsor":"The Forsyth Institute","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ The Forsyth Institute","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ The Forsyth Institute"},{"orgOrder":0,"company":"HysensBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ Undisclosed"},{"orgOrder":0,"company":"Byoung-Moo Seo","sponsor":"HysensBio","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Byoung-Moo Seo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Byoung-Moo Seo \/ HysensBio","highestDevelopmentStatusID":"8","companyTruncated":"Byoung-Moo Seo \/ HysensBio"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Meridol","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ Undisclosed"},{"orgOrder":0,"company":"Arcadia Consumer Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Arcadia Consumer Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcadia Consumer Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcadia Consumer Healthcare \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PROCTER AND GAMBLE

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            PROCTER AND GAMBLE

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Fluoride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control.

                            Details : Sodium fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gingivitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 25, 2025

                            Lead Product(s) : Sodium Fluoride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Byoung-Moo Seo

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Byoung-Moo Seo

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KH001

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : HysensBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Physiologic Dentin Regeneration and Safety of KH001 in the Administration of Erupted Wisdo...

                            Details : KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dental Caries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 30, 2024

                            Lead Product(s) : KH001

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : HysensBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Colgate Palmolive

                            India arrow
                            The MedTech Conference
                            Not Confirmed

                            Colgate Palmolive

                            India arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Investigation to Assess the Efficacy of Manual Toothbrushes in the Reduction of Plaque and Gingivitis...

                            Details : This drug candidate is currently being evaluated in phase II clinical studies for the treatment of Dental Plaque.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 22, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Colgate Palmolive

                            India arrow
                            The MedTech Conference
                            Not Confirmed

                            Colgate Palmolive

                            India arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meridol

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of Toothpaste Containing Zinc Lactate as Compared to Colgate Cavity Protection Toothpaste.

                            Details : Meridol is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gingivitis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 21, 2024

                            Lead Product(s) : Meridol

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MeiraGTx

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            MeiraGTx

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV2-hAQP1

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

                            Details : AAV2-hAQP1 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Xerostomia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 09, 2024

                            Lead Product(s) : AAV2-hAQP1

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HysensBio

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            HysensBio

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KH001

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : The Forsyth Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of KH001 in Long-term Relief from Dentin Hypersensitivity

                            Details : KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dentin Sensitivity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2024

                            Lead Product(s) : KH001

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : The Forsyth Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HysensBio

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            HysensBio

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KH001

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity

                            Details : KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dentin Sensitivity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 20, 2024

                            Lead Product(s) : KH001

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MeiraGTx

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            MeiraGTx

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV2-hAQP1

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

                            Details : AAV2-hAQP1 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Xerostomia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : AAV2-hAQP1

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Advantage Silver Dental Arrest

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Advantage Silver Dental Arrest

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Silver Diamine Fluoride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : University of Washington

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Advantage Arrest in Healthy Children 13-Months to 13-Years of Age

                            Details : Silver Diamine Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dental Caries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2023

                            Lead Product(s) : Silver Diamine Fluoride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : University of Washington

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Arcadia Consumer Healthcare

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Arcadia Consumer Healthcare

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorite

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI a...

                            Details : Sodium chlorite is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gingivitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 28, 2022

                            Lead Product(s) : Chlorite

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth